An anti-cancer compound developed at USA Health Mitchell Cancer Institute is showing promise in pre-clinical studies – one involving pancreatic cancer and the other involving breast cancer. The compound, MCI-715, was developed by Gary Piazza, Ph.D., and his lab team at the Drug Discovery Research Center at MCI.
Cancer Care at USA Health
At USA Health Mitchell Cancer Institute in Mobile, Ala., medical and radiation oncologists, hematologists, surgeons and other cancer specialists work together to provide diagnosis, staging, surgery and advanced cancer treatment options to our patients. Each physician is a disease-focused expert, which means we can offer every patient a more specialized degree of care.
We approach the treatment of our patients as a team, bringing together physicians, nurses, radiologists, pathologists, researchers and other specialists in a weekly tumor conference to discuss new diagnoses, recurrent cancers and challenging cases. From these meetings emerges a course of treatment that is guided by the collective expertise of the team, as well as National Comprehensive Cancer Network (NCCN) guidelines.
As an academic medical center, USA Health offers continuous research, clinical trials, education of our medical staff and programs promoting cancer control and prevention. We see the most complex, difficult and challenging cases on a daily basis, which puts us in a position to provide the most advanced and appropriate course of treatment for each patient.
At Mitchell Cancer Institute, we create multidisciplinary support teams to help guide patients and their families through their care journey. Our comprehensive care includes social and financial services, psychological care, nutritional counseling, chaplains, physical therapy, palliative care, support groups and more.